News

CSMG Technologies Live Tissue Connect Receives ISO Certification; Certification is a Major Milestone Towards Achieving CE Mark

Corpus Christi, TX, May 16, 2008 -- CSMG Technologies, Inc., (OTCBB: CTGI - News), a technology management company, announced that its Live Tissue Connect ("LTC") subsidiary has received their ISO 13485:2003 certification for the design and manufacture of Bipolar Forceps Systems. This Quality Management System certificate was issued by BSI Management Systems, one of the world's leading certification bodies.
Don Robbins, President and CEO of CSMG Technologies said, "LTC has been awarded this ISO certification designation in recognition of their commitment to quality designs, products, processes, and service for our customers. As we progress towards achieving CE Mark in Europe, the LTC team is developing LTC's marketing and sales channels as well."

Frank D'Amelio, President of LTC, "As a result of the hard work and dedication of our Santa Barbara staff, our company's Quality Management System meets the standard of ISO 13485:2003. This is the international standard recognized for medical device regulations around the world. Having a Quality Management System that is in compliance with ISO 13485 is a requirement before one can be audited to and apply for a CE mark. Our next objective will be to pass another audit, required prior to allowing us to CE mark our Bipolar Forceps System."

About Live Tissue Connect
LTC's surgical tissue bonding/welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC holds approximately 31 patents and pending patents in the U.S., Australia, Canada, European Union, Ukraine, and other countries.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.
Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: www.csmgtechinternational.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

 

 

 

 

 

 


 


LTC™, LIVE TISSUE CONNECT™, BioFuse™ their related Logos, and other indicia of origin are trademarks of Live Tissue Connect, Inc. All logos, text, graphics, and videos are also the subject of copyright (c) 2008 of Live Tissue Connect, Inc. All rights reserved. Privacy Policy and Terms of Use